Neuromuscular disorder is an umbrella term covering many conditions linked to multiple genetic mutations. In this test-specific episode of the "Answers From the Lab" podcast, Zhiyv (Neal) Niu, Ph.D., and Christopher Klein, M.D., explain how Mayo Clinic Laboratories' updated neuromuscular gene panel informs precise diagnosis for optimal patient care.

"The neuromuscular gene panel offers a more comprehensive phenotype analysis than other tests on the market," Dr. Niu says. "We analyze 217 genes — the most complete list of neuromuscular genes and their mutations — to detect single nucleotide variants, insertion deletions, and copy number events."

The phenotype-based test design draws on the expertise of Mayo Clinic neurologists.

"Our clinical experience has highlighted the range of genotype-phenotype correlation," Dr. Klein says. "The completeness and accuracy of this panel allows us to avoid mistakes in our diagnoses and guide patients to treatment options that weren't available in the past."

Listen to learn more about Mayo Clinic Laboratories' updated neuromuscular gene panel.

Note: Podcasts will not playback on Internet Explorer. Please use an alternative web browser, or listen from your mobile device on a preferred listening app.

Testing

MUPAN | Comprehensive Neuromuscular Gene Panel, Varies

Useful information

Establishing a molecular diagnosis for patients with a neuromuscular disorder.

Identifying variants within genes known to be associated with neuromuscular disorders allowing for predictive testing of at-risk family members.

Specimen requirements

• Specimen Type: Whole Blood
• Patient Preparation: A previous bone marrow transplant from an allogenic donor will interfere with testing. Call 800-533-1710 for instructions for testing patients who have received a bone marrow transplant.
• Container/Tube: Lavender top (EDTA) or yellow top (ACD)

Acceptable:

• Any anticoagulant
• Specimen Volume: 3 mL
• Collection Instructions:
  1. Invert several times to mix blood.
  2. Send whole blood specimen in original tube. Do not aliquot.
• Specimen Stability Information: Ambient (preferred)/Refrigerated

Additional Information: If a cord blood specimen is received, MATCC / Maternal Cell Contamination, Molecular Analysis, Varies will be performed at an additional charge; maternal blood sample is required.

Performance information

Analytic time: 28 to 42 days

Days performed: Varies

The latest from Test in Focus

Unique Test Screens for Recently Identified Peripheral Neuropathy: Matthew Schultz, Ph.D., and Amy White, M.S., CGC

September 24, 2024

Matthew J. Schultz, Ph.D., and Amy L. White, M.S., CGC, explain how Mayo Clinic Laboratories' unique urine assay (Mayo ID: SORD) screens for peripheral neuropathy arising from SORD gene variants. Although recently identified, SORD-related peripheral neuropathy is fairly common.

Panel Detects Demyelinating Neuropathy Biomarkers: John Mills, Ph.D., and Divyanshu Dubey, M.B.B.S.

September 17, 2024

John Mills, Ph.D., and Divyanshu Dubey, M.B.B.S., explain how Mayo Clinic Laboratories' new test panel can distinguish among various potential causes of demyelinating neuropathies. Test results are important for managing these devastating autoimmune conditions.

Genetic Tests Identify Risk of Fluoropyrimidine-Induced Toxicity: Ann Moyer, M.D., Ph.D.

September 10, 2024

Ann Moyer, M.D., Ph.D., explains how Mayo Clinic Laboratories' unique genetic tests identify patients at high risk of severe reactions to fluoropyrimidines — a type of chemotherapy drug. Test results can guide clinical decision-making for safer cancer treatment.

View MoreView Less